Targeting the mTOR Pathway in Leukemia-Reference-Cited by-同舟云学术

Targeting the mTOR Pathway in Leukemia

Published:2016-04-06 Issue:8 Volume:117 Page:1745-1752
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J. Cell. Biochem.

Author:

Dinner Shira¹,Platanias Leonidas C.¹²

Affiliation:

1. Division of Hematology-Oncology; Robert H. Lurie Comprehensive Cancer Center; Feinberg School of Medicine; Northwestern University; Chicago Illinois 60611

2. Department of Medicine; Jesse Brown Veterans Affairs Medical Center; Chicago Illinois 60612

Funder

National Institutes of Health Grants

Department of Veterans Affairs

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcb.25559/fullpdf

Reference86 articles.

1. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor;Airiau;Cell Death Dis,2013

2. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia;Allegretti;Sci Rep,2015

3. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors;Altman;Clin Cancer Res,2011

4. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting;Altman;Clin Cancer Res,2014

5. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107);Amadori;Br J Haematol,2012

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review;Medical Oncology;2024-08-09

2. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-01

3. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities;Cancers;2023-11-05

4. Mechanism of Procyanidin B2 in the Treatment of Chronic Myeloid Leukemia Based on Integrating Network Pharmacology and Molecular Docking;Anti-Cancer Agents in Medicinal Chemistry;2023-10

5. In the Pipeline: Emerging Therapy for CML;Pathogenesis and Treatment of Leukemia;2023